{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:24:19Z","timestamp":1773681859312,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop a multivariable model assessing factors predicting a second\u2010dose response to eptinezumab treatment over weeks 13\u201324 in patients with migraine initially reporting a suboptimal response over weeks 1\u201312.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eptinezumab is a monoclonal antibody used for migraine prevention, administered every 12\u00a0weeks. In the PROMISE\u20101 and PROMISE\u20102\u00a0studies, the first\u2010dose response to eptinezumab treatment (\u226550% monthly migraine day [MMD] reduction over weeks 1\u201312) occurred in ~50\u201360% of patients with episodic (EM) and chronic migraine (CM), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis included patients with suboptimal first\u2010dose response (&lt;50% MMD reduction over weeks 1\u201312) with EM and CM, with patient\u2010reported outcome data at weeks 12 and 24. Eptinezumab 100 and 300\u00a0mg doses were pooled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis included 416\/888 patients (46.8%) from PROMISE\u20101 and 479\/1072 patients (44.7%) from PROMISE\u20102 with suboptimal first\u2010dose response. The proportion of suboptimal first\u2010dose responders who were second\u2010dose responders was 37.0% (71\/192; eptinezumab) and 33.9% (42\/124; placebo) in PROMISE\u20101 and 28.8% (79\/274) and 18.5% (38\/205) in PROMISE\u20102. Significant first\u2010dose predictors of second\u2010dose response were percent change in MMDs across weeks 1\u201312 (PROMISE\u20101, odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.95, 0.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.0001; PROMISE\u20102, OR: 0.94, CI: 0.92, 0.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001) and change in 6\u2010item Headache Impact Test (HIT\u20106) total score (PROMISE\u20102 only, OR: 0.92; CI: 0.87, 0.98;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.027). In PROMISE\u20101, the probability of second\u2010dose response ranged from 21.7% in patients with first\u2010dose 0% MMD change to 56.0% in patients with first\u2010dose 45% MMD reduction. In PROMISE\u20102, depending on HIT\u20106 total score, probability of second\u2010dose response ranged from 5.9\u201312.1% in patients with first\u2010dose 0% MMD change to 54.2%\u201372.3% in patients with first\u2010dose 45.0% MMD reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals with migraine not experiencing \u226550% MMD response to their first dose of eptinezumab may benefit from a second dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14302","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T01:35:58Z","timestamp":1651887358000},"page":"558-565","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo\u2010controlled randomized clinical trials"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2661-0643","authenticated-orcid":false,"given":"Jack D.","family":"Schim","sequence":"first","affiliation":[{"name":"Headache Center of Southern California  Carlsbad California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlton","family":"Anderson","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Brunner","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Pacific Northwest Statistical Consulting  Woodinville Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Ogbru","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lora","family":"McGill","sequence":"additional","affiliation":[{"name":"CNS HealthCare  Memphis Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414552532"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01770.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"e_1_2_11_10_1","volume-title":"User's Manual for the SF\u201036v2\u00ae Health Survey","author":"Ware J","year":"2007"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_11_12_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13946"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000110117"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00296-2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-007-0360-4"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050560"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006175"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.023"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14302","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:06:20Z","timestamp":1762088780000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/head.14302"],"URL":"https:\/\/doi.org\/10.1111\/head.14302","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}